FDA rejects Adamis opioid overdose therapy Zimhi, hitting share price

Shares in Adamis Pharmaceuticals have been poleaxed by an FDA decision to reject Zimhi, intended as a treatment for overdoses of opioid painkillers, because of manufacturing issues.